Quick Answer
Lineage Cell Therapeutics, Inc. reported Diluted EPS of $0.28 per share (loss) for fiscal year 2025.
Lineage Cell Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.28 | -211.1% |
| 2024 | -$0.09 | +25.0% |
| 2023 | -$0.12 | +20.0% |
| 2022 | -$0.15 | +11.8% |
| 2017 | -$0.17 | -150.0% |
| 2016 | $0.34 | +157.6% |
| 2015 | -$0.59 | -7.3% |
| 2014 | -$0.55 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.13 | -550.0% | +0.0% |
| June 30, 2025 | -$0.13 | -333.3% | -550.0% |
| March 31, 2025 | -$0.02 | +50.0% | +0.0% |
| September 30, 2024 | -$0.02 | +50.0% | +33.3% |
| June 30, 2024 | -$0.03 | +0.0% | +25.0% |
| March 31, 2024 | -$0.04 | -33.3% | +0.0% |
| September 30, 2023 | -$0.04 | +0.0% | -33.3% |
| June 30, 2023 | -$0.03 | +25.0% | +0.0% |
- Lineage Cell Therapeutics, Inc. showed a decrease of -211.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2014–2025 period, Lineage Cell Therapeutics, Inc.’s diluted eps has grown by 49.1% (from $0.55 per share (loss) to $0.28 per share (loss)).
- The most recent figure is from Lineage Cell Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: